Which statement is NOT true of EFAD in patients with cystic fibrosis?

Which statement is NOT true of EFAD in patients with cystic fibrosis?

• A. Biochemical EFAD may be seen in both pancreatic sufficient and insufficient patients
• B. Routine supplementation of omega-3 fatty acids is essential in the management of CF
• C. Those patients with moderate to severe lung disease are at high risk for EFAD
• D. Poor growth and pulmonary status correlate with biochemical markers of EFAD

Answer: (B)

Essential fatty acid deficiency in cystic fibrosis stems from fat malabsorption due to pancreatic insufficiency and the increased energy needs of chronic illness. EFAD can be detected biochemically even in patients who appear pancreatic-sufficient, and those with moderate to severe lung disease are at higher risk because their overall nutritional demand and fat malabsorption tend to be greater. Growth failure and worse pulmonary status commonly accompany biochemical EFAD because lacking essential fatty acids affects growth, immune function, and lung health, reinforcing the link between nutritional status and disease severity. Routine supplementation with omega-3 fatty acids is not considered essential in standard CF management. While omega-3s may be used as an adjunct for potential anti-inflammatory benefits, the core approach to preventing EFAD focuses on optimizing fat absorption with pancreatic enzyme replacement and ensuring adequate fat-soluble vitamin supplementation.

Essential fatty acid deficiency in cystic fibrosis stems from fat malabsorption due to pancreatic insufficiency and the increased energy needs of chronic illness. EFAD can be detected biochemically even in patients who appear pancreatic-sufficient, and those with moderate to severe lung disease are at higher risk because their overall nutritional demand and fat malabsorption tend to be greater. Growth failure and worse pulmonary status commonly accompany biochemical EFAD because lacking essential fatty acids affects growth, immune function, and lung health, reinforcing the link between nutritional status and disease severity.

Routine supplementation with omega-3 fatty acids is not considered essential in standard CF management. While omega-3s may be used as an adjunct for potential anti-inflammatory benefits, the core approach to preventing EFAD focuses on optimizing fat absorption with pancreatic enzyme replacement and ensuring adequate fat-soluble vitamin supplementation.